title: Cutaneous toxicities of RAF inhibitors.
abstract: The RAF inhibitors vemurafenib and dabrafenib are emerging as the standard of care for Val600 BRAF-mutant metastatic melanoma. These drugs have shown clinical benefit over the standard care (dacarbazine); however, they are associated with frequent cutaneous adverse events, which can be concerning to the patient and their physician. Herein, we review the range of cutaneous disorders that seem to be induced by RAF inhibitors, including cutaneous squamous-cell carcinoma, hyperkeratotic lesions, Grover's disease, keratosis pilaris-like reactions, and photosensitivity. These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors.
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.
authors.forename: Rachael
authors.initials: R
authors.lastname: Anforth
authors.forename: Pablo
authors.initials: P
authors.lastname: Fernandez-Peñas
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
mesh_terms: D000015:Abnormalities, Multiple / Q000139:chemically induced; D000051:Acantholysis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D007644:Darier Disease / Q000139:chemically induced; D005138:Eyebrows / Q000002:abnormalities; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D007093:Imidazoles / Q000008:administration & dosage / Q000633:toxicity*; D007211:Indoles / Q000008:administration & dosage / Q000633:toxicity*; D007642:Keratosis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D010091:Oximes / Q000008:administration & dosage / Q000633:toxicity*; D010787:Photosensitivity Disorders / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D013449:Sulfonamides / Q000008:administration & dosage / Q000633:toxicity*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib